Jan. 10, 2015
Below are current clinical trials.1 studies in Hepatopulmonary syndrome
(open studies only).
Filter this list of studies by location, status and more.
Rochester, Minn., Scottsdale/Phoenix, Ariz.
Sorafenib for Hepatopulmonary Syndrome
Study type: Interventional What is this?
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase: II What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.
About this study
The main purpose of this clinical trial is to determine the safety and effects of the study drug, sorafenib, in adults diagnosed with hepatopulmonary syndrome (HPS). The study will evaluate how well the drug is tolerated and its effect on the level of oxygen in the blood and the function of the lung vessels.
Participating Mayo Clinic locations
Study statuses change often. Please contact us for help.
Print study details
- Rochester, Minnesota: 13-008768
- Scottsdale/Phoenix, Arizona: 13-008768
NCT ID: NCT02021929
Sponsor Protocol Number: 13-008768
- Lange PA, et al. Hepatopulmonary syndrome: Prevalence, causes, clinical manifestations and diagnosis. http://www.uptodate.com/home. Accessed Nov. 22, 2014.
- Lange PA, et al. Hepatopulmonary syndrome: Natural history, treatment and outcomes. http://www.uptodate.com/home. Accessed Nov. 22, 2014.
- Liver transplant. Mayo Clinic. http://www.mayoclinic.org/liver-transplant/statistics.html. Accessed Nov. 22, 2014.
- Krowka MJ, et al. Pulmonary contraindications, indications and MELD exceptions for liver transplantation: A contemporary view and look forward. Journal of Hepatology. 2013;59:367.
- Ferri FF. Ferri's Clinical Advisor 2015: 5 Books in 1. Philadelphia, Pa.: Mosby Elsevier; 2015. https://www.clinicalkey.com. Accessed Nov. 23, 2014.
- Iyer VN, et al. Hepatopulmonary syndrome: Favorable outcomes in the MELD exception era. Hepatology 2013;57:2427.